ABclonal
PrivateLast Round
Series D
Dec 8, 2021
Total Funding Raised
$284.02M
Company Overview
ABclonal operates in Healthcare & Life Sciences and is based in Wuhan. Its latest recorded funding round was a Series D round in December 2021.
ABclonal is a biotechnology company that manufactures life science reagents, including antibodies, recombinant proteins, ELISA kits, and molecular biology enzymes, while providing contract research organization (CRO) services for scientific research and diagnostic applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ABclonal Comparables
Compare ABclonal with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cell Signaling Technology | 83% | |
| Sino Biological Inc. | 83% | |
| Proteintech Group | 82% |
For institutional investors. Book with your work email.
ABclonal Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Dec 8, 2021 | ||||
| Series C | Feb 22, 2021 | ||||
| Series B | Aug 1, 2016 | ||||
| Series A | Mar 1, 2016 |
For institutional investors. Book with your work email.
ABclonal Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Loyal Valley Capital | Series D |
| Oriza FOFs | Series C |
| LYFE Capital | Series C |
| C&D Emerging Industry Equity Investment | Series C |
| Beijing Taikang Investment Management Co., Ltd. | Series D |
| Sigma Square Capital | Series C |
| HongShan Capital Group (HSG) | Series D, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 22, 2021
$93M round led by LYFE Capital and HongShan.
For institutional investors. Book with your work email.
ABclonal Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ABclonal's valuation, stock price, and market status.
Is ABclonal a public or private company?
ABclonal is a private company.
What is the current stock price of ABclonal?
ABclonal is a private company, so its shares have no public market price. Caplight tracks ABclonal's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ABclonal worth (valuation)?
Valuation information for ABclonal is not publicly available.
Can I buy ABclonal stock?
ABclonal shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ABclonal's last funding round?
ABclonal's most recent funding round was Series D on December 8, 2021.
Who are the main investors in ABclonal?
Key investors in ABclonal include LYFE Capital, HongShan Capital Group (HSG).
Will ABclonal IPO soon?
No public IPO plans have been announced for ABclonal.
How can I track ABclonal secondary market activity?
Caplight tracks bids, offers, and trades in ABclonal's shares on secondary markets.